Zusammenfassung
Bereits seit den 1940er Jahren werden symptomatische Knochenmetastasen mit osteotropen Radio-Tracern effektiv behandelt. Bei ca. 70% der Patienten kann eine deutliche Schmerzreduktion für längere Zeit erzielt werden. In Kombination mit Bisphosphonaten oder Chemotherapie sowie bei frühzeitigem und wiederholtem Einsatz der Radionuklidtherapie kann eine verbesserte Wirkung erzielt werden. Mit dem Alphaemitter Ra-223-Chlorid konnte auch das Gesamtüberleben verbessert werden. Knochenmetastasen von Schilddrüsenkarzinomen und neuroendokrinen Tumoren lassen sich mit tumorspezifischen Radiopharmaka behandeln. Die direkte Adressierung von Knochenmetastasen beim multiplen Myelom, Prostata-, Mamma- und Lungenkarzinom ist grundsätzlich möglich, muss jedoch noch systematisch evaluiert werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Bodei L, Lam M, Chiesa C et al (2008) EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35(10): 1934–1940
Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ (2005) Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Medicine Commun 26(11): 969–976
Chatterjee M, Chakraborty T, Tassone P (2006) Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. Eur J Cancer 42(11): 1640–1652
Couturier O, Faivre-Chauvet A, Filippovich IV et al (1999) Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res 5(10 Suppl): 3165s–3170s
Dafermou A, Colamussi P, Giganti M et al (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28(7): 788–798
DGN (Deutsche Gesellschaft für Nuklearmedizin) Leitlinien. www.nuklearmedizin.de
Durante C, Haddy N, Baudin E et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91(8): 2892–2899
Ezziddin S, Sabet A, Heinemann F et al (2011) Response and long-term control of bone metastases after peptide receptor radionuclide therapy with(177)Lu-octreotate. J Nucl Med 52(8): 1197–1203
Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6(6): 392–400
Gonias S, Goldsby R, Matthay KK et al (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27(25): 4162–4168
Kraeber-Bodere F, Campion L, Rousseau C et al (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27(10): 1487–1493
Lam MG, Dahmane A, Stevens WH et al (2008) Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35(4): 756–765
Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28(8): 623–630
McDevitt MR, Finn RD, Ma D et al (1999) Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med 40(10): 1722–1727
Navalkissoor S, Alhashimi DM, Quigley AM et al (2010) Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37(5): 904–912
Nilsson S, Strang P, Aksnes AK et al (2012) A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 48(5): 678–686
Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: 213–223
Petrich T, Widjaja A, Musholt TJ et al (2001) Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 28(2): 203–208
Ricci S, Boni G, Pastina I et al (2007) Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 34(7): 1023–1030
Robinson RG, Preston DF, Schiefelbein M, Baxter KG (1995) Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274(5): 420–424
Rousseau C, Ferrer L, Supiot S et al (2012) Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 33(3): 679–688
Sartor O, Reid RH, Bushnell DL et al (2007) Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109(3): 637–643
Schlumberger M, Challeton C, De Vathaire F et al (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37(4): 598–605
Schoeneich G, Muller SC, Palmedo H (1998) Indications for nuclear medicine therapy in advanced prostate carcinoma. Urologe A 37(2): 162–166
Sciuto R, Festa A, Pasqualoni R et al (2001) Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 66(2): 101–109
Sciuto R, Festa A, Rea S et al (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43(1): 79–86
Storto G, Klain M, Paone G et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39(1): 35–41
Tu SM, Millikan RE, Mengistu B et al (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 (9253): 336–341
Van Tol KM, Hew JM, Jager PL et al (2000) Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxford) 52(5): 653–659
Van Vliet EI, Hermans JJ, de Ridder MA et al (2012) Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions. J Nucl Med 53(9): 1359–1366
Van Vliet EI, Teunissen JJ, Kam BL et al (2013) Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 97(1): 74–85
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kotzerke, J., Brogsitter, C. (2014). Radionuklide in der Therapie von Knochenmetastasen. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-43471-0_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43470-3
Online ISBN: 978-3-662-43471-0
eBook Packages: Medicine (German Language)